Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Epemolu

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Advances in Experimental Medicine and Biology|January 1, 1994
Iron chelator designR C Hider, O Epemolu, S Singh, et al.
European Journal of Drug Metabolism and Pharmacokinetics|January 1, 1996
Metabolism and pharmacokinetics of 1-(2'-hydroxy-ethyl)- and 1-(3'-hydroxypropyl)-2-ethyl-3-hydroxypyridin-4-ones in the ratS Singh, R Choudhury, R O Epemolu, et al.
American Journal of Clinical Pathology|September 1, 1987
Ethanol ingestion inhibits human whole blood platelet impedance aggregationD P Mikhailidis, M A Barradas, O Epemolu, et al.
Journal of Chromatography|January 3, 1992
High-performance liquid chromatographic determination of 1,2-diethyl-3-hydroxypyridin-4-one and its 2-(1-hydroxyethyl) metabolite in rat bloodR O Epemolu, S Singh, R C Hider, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 1, 1997
Metabolism and pharmacokinetics of 1-(2'-trimethylacetoxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP117) in the ratR Choudhury, R O Epemolu, B L Rai, et al.
British Journal of Haematology|December 1, 1987
Comparison of the platelet pro-aggregatory effect of conventional unfractionated heparins and a low molecular weight heparin fraction (CY 222)M A Barradas, D P Mikhailidis, O Epemolu, et al.
Advances in Experimental Medicine and Biology|January 1, 1994
Lessons from preclinical and clinical studies with 1,2-diethyl-3-hydroxypyridin-4-one, CP94 and related compoundsJ B Porter, S Singh, K P Hoyes, et al.
Journal of Pharmaceutical and Biomedical Analysis|July 1, 1994
HPLC determination of 1,2-diethyl-3-hydroxypyridin-4-one (CP94), its iron complex [Fe(III) (CP94)3] and glucuronide conjugate [CP94-GLUC] in serum and urine of thalassaemic patientsR O Epemolu, R Ackerman, J B Porter, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 1, 1992
Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-onesS Singh, R O Epemolu, P S Dobbin, et al.
Journal of Medicinal Chemistry|August 10, 2001
The first potent and selective inhibitors of the glycine transporter type 2W L Caulfield, I T Collie, R S Dickins, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Advances in Experimental Medicine and Biology|January 1, 1994
Iron chelator designR C Hider, O Epemolu, S Singh, et al.
European Journal of Drug Metabolism and Pharmacokinetics|January 1, 1996
Metabolism and pharmacokinetics of 1-(2'-hydroxy-ethyl)- and 1-(3'-hydroxypropyl)-2-ethyl-3-hydroxypyridin-4-ones in the ratS Singh, R Choudhury, R O Epemolu, et al.
American Journal of Clinical Pathology|September 1, 1987
Ethanol ingestion inhibits human whole blood platelet impedance aggregationD P Mikhailidis, M A Barradas, O Epemolu, et al.
Journal of Chromatography|January 3, 1992
High-performance liquid chromatographic determination of 1,2-diethyl-3-hydroxypyridin-4-one and its 2-(1-hydroxyethyl) metabolite in rat bloodR O Epemolu, S Singh, R C Hider, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 1, 1997
Metabolism and pharmacokinetics of 1-(2'-trimethylacetoxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP117) in the ratR Choudhury, R O Epemolu, B L Rai, et al.
British Journal of Haematology|December 1, 1987
Comparison of the platelet pro-aggregatory effect of conventional unfractionated heparins and a low molecular weight heparin fraction (CY 222)M A Barradas, D P Mikhailidis, O Epemolu, et al.
Advances in Experimental Medicine and Biology|January 1, 1994
Lessons from preclinical and clinical studies with 1,2-diethyl-3-hydroxypyridin-4-one, CP94 and related compoundsJ B Porter, S Singh, K P Hoyes, et al.
Journal of Pharmaceutical and Biomedical Analysis|July 1, 1994
HPLC determination of 1,2-diethyl-3-hydroxypyridin-4-one (CP94), its iron complex [Fe(III) (CP94)3] and glucuronide conjugate [CP94-GLUC] in serum and urine of thalassaemic patientsR O Epemolu, R Ackerman, J B Porter, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 1, 1992
Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-onesS Singh, R O Epemolu, P S Dobbin, et al.
Journal of Medicinal Chemistry|August 10, 2001
The first potent and selective inhibitors of the glycine transporter type 2W L Caulfield, I T Collie, R S Dickins, et al.
Pageof 2